E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute Ischemic Stroke |
Accidente cerebrovascular isquémico agudo |
|
E.1.1.1 | Medical condition in easily understood language |
Acute Ischemic Stroke |
Accidente cerebrovascular isquémico agudo |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055221 |
E.1.2 | Term | Ischemic stroke |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess the effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of independence and activities of daily life |
El objetivo principal del estudio es evaluar los efectos de natalizumab frente a placebo en el accidente cerebrovascular isquémico agudo, en cuanto a las medidas clínicas de independencia y actividades de la vida diaria. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following measures of independence, activities of daily living, neurologic function, quality of life, and cognition and safety and tolerability. |
El objetivo secundario del estudio es investigar la respuesta a la dosis y a la exposición, así como los efectos clínicos del tratamiento de natalizumab frente a placebo en el accidente cerebrovascular isquémico agudo en cuanto a las siguientes medidas de independencia, actividades de la vida diaria, función neurológica, calidad de vida y cognición, seguridad y tolerabilidad. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ?9 hours prior to study treatment initiation - Score of 5 to 23 points, inclusive, on the NIHSS at Screening - Prior to index stroke, patient was able to perform basic activities of daily living without assistance - For those subjects who underwent a cranial MRI, there is at least 1 acute infarct with a diameter of ?2 cm on baseline brain diffusion-weighted imaging NOTE: Other protocol-defined inclusion criteria may apply. |
-Diagnóstico clínico de accidente cerebrovascular isquémico agudo supratentorial definido por el UMCN a ?9 horas antes del inicio del tratamiento del estudio. -Puntuación de 5 a 23 puntos, ambos inclusive, en la NIHSS en el momento de la selección. -Antes del accidente cerebrovascular de referencia, el paciente era capaz de realizar las actividades básicas de la vida diaria sin ayuda. -En los sujetos sometidos a una RM craneal, hay al menos 1 infarto agudo con un diámetro de ?2 cm en las imágenes cerebrales ponderadas por difusión iniciales. NOTA: Otros criterios definidos en el protocolo pueden aplicar. |
|
E.4 | Principal exclusion criteria |
- Rapidly improving or minor stroke symptoms - Lacunar or isolated brainstem stroke based on clinical assessment and available acute imaging studies - Presence of acute intracranial hemorrhage on acute brain CT or MRI - Severe stroke NOTE: Other protocol-defined exclusion criteria may apply. |
-Síntomas de accidente cerebrovascular menores o que mejoran rápidamente. -Accidente cerebrovascular del tronco encefálico lacunar o aislado según la evaluación clínica y los estudios por imagen del momento agudo disponibles -Presencia de hemorragia intracraneal aguda en la TAC o la RM cerebral aguda -Accidente cerebrovascular grave NOTA: |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is a composite global measure of functional disability based on a score of 0 or 1 on the mRS and a score of ?95 on the BI at Day 90 |
El criterio de valoración de eficacia principal es una medida global compuesta de la discapacidad funcional, basada en una puntuación de 0 o 1 en la escala de Rankin modificada (mRS) y una puntuación ?95 en el Índice de Barthel (IB) el día 90 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are: - mRS score at Day 90 - BI score at Day 90 - SIS-16 score at Day 90 - MoCA score at Day 90 - Safety (incidence and proportion of AEs and SAEs) - NIHSS score at Day 90 |
Los criterios de valoración secundarios son: -Puntuación de la mRS el día 90 -Puntuación del IB el día 90 -Puntuación de la Escala de impacto del accidente cerebrovascular 16 el día 90 -Puntuación de la Evaluación cognitiva de Montreal el día 90 -Seguridad (incidencia y porcentajes de acontecimientos adversos y acontecimientos adversos graves) -Puntuación de la Escala de accidentes cerebrovasculares del National Institute of Health (National Institute of Health Stroke Scale, NIHSS) el día 90 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- mRS score: Day 90 - BI score: Day 90 - SIS-16 score: Day 90 - MoCA score: Day 90 - AEs and SAEs: throughout the study, as necessary - NIHSS score at Day 90 |
-Puntuación de la mRS el día 90 - Puntuación del IB el día 90 - Puntuación de la Escala de impacto del accidente cerebrovascular 16 el día 90 - Puntuación de la Evaluación cognitiva de Montreal el día 90 - Seguridad (incidencia y porcentajes de acontecimientos adversos y acontecimientos adversos graves) - Puntuación de la Escala de accidentes cerebrovasculares del National Institute of Health (National Institute of Health Stroke Scale, NIHSS) el día 90 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |